

HepaFat-AI Incorporated into Blackford Analysis Partner Agreement

Resonance Health Ltd (ASX: RHT) (“Resonance Health” or “Company”) advises that its artificial intelligence medical device software, HepaFat-AI, has been added as a Resonance Health product available for distribution and promotion by Blackford Analysis Inc. (formerly Blackford Analysis Limited) (“Blackford”) under the Alliance Partner Agreement (“Agreement”) entered into between the Company and Blackford in 2018 (refer ASX announcement dated 5 July 2018).

HepaFat-AI recently received 510(k) regulatory clearance from the US Food and Drug Administration (“FDA”) allowing for its commercial sale in the United States of America (refer ASX announcement dated 9 December 2020). HepaFat-AI is a fully automated artificial intelligence (“AI”) fatty-liver assessment device that measures the volumetric liver fat fraction (“VLFF”), proton density fat fraction (“PDFF”) and steatosis grade in individuals with confirmed or suspected fatty liver disease. When interpreted by a trained physician, the HepaFat-AI results can be used to monitor liver fat content in patients undergoing weight loss management, and to aid in the assessment and screening of living donors for liver transplant.

Blackford delivers a dedicated platform and service for the effective selection, deployment, orchestration, and use of medical imaging applications and AI. This enables healthcare providers to quickly access and manage medical image analysis applications and AI algorithms that add clinical value. The Agreement allows Blackford’s current and future customers access to HepaFat-AI and other Resonance Health products via the Blackford platform and their channel partners such as Intelera and eRAD. The Company looks forward to continuing to work with the Blackford team to deliver service to radiologists.

Additional information on HepaFat-AI and its application in confirmed or suspected fatty liver disease is available on our product-specific website, www.hepafat.com.

Authorised by:

This announcement has been authorised for release in accordance with the delegated authority of the Board of Directors of Resonance Health.

For further information please contact:

Chad Tondut

Communications Manager, Resonance Health

E: chadt@resonancehealth.com P: +61 (0)8 9286 5300